These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Prospects for pharmacotherapy of schizophrenia. Pickar D Lancet; 1995 Mar; 345(8949):557-62. PubMed ID: 7539875 [No Abstract] [Full Text] [Related]
6. An assessment of iloperidone for the treatment of schizophrenia. Jain KK Expert Opin Investig Drugs; 2000 Dec; 9(12):2935-43. PubMed ID: 11093363 [TBL] [Abstract][Full Text] [Related]
7. Schizophrenia: The drug deadlock. Abbott A Nature; 2010 Nov; 468(7321):158-9. PubMed ID: 21068804 [No Abstract] [Full Text] [Related]
11. New atypical antipsychotics for schizophrenia: iloperidone. Caccia S; Pasina L; Nobili A Drug Des Devel Ther; 2010 Feb; 4():33-48. PubMed ID: 20368905 [TBL] [Abstract][Full Text] [Related]
12. An update on the efficacy and safety of iloperidone as a schizophrenia therapy. Nair A; Salem A; Asamoah AL; Gosal R; Grossberg GT Expert Opin Pharmacother; 2020 Oct; 21(15):1793-1798. PubMed ID: 32735148 [TBL] [Abstract][Full Text] [Related]
13. Signalling profile differences: paliperidone versus risperidone. Clarke WP; Chavera TA; Silva M; Sullivan LC; Berg KA Br J Pharmacol; 2013 Oct; 170(3):532-45. PubMed ID: 23826915 [TBL] [Abstract][Full Text] [Related]
14. Atypical antipsychotics: the two new arrivals. Roman MW Issues Ment Health Nurs; 2011; 32(1):85-6. PubMed ID: 21208056 [No Abstract] [Full Text] [Related]
15. Risperidone, a new antipsychotic with serotonin 5-HT2 and dopamine D2 antagonistic properties. Heylen SL; Gelders YG Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():180A-181A. PubMed ID: 1379877 [No Abstract] [Full Text] [Related]
16. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats. Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429 [TBL] [Abstract][Full Text] [Related]
17. Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha 2C, 5-HT6, and 5-HT1A receptors. Kalkman HO; Feuerbach D; Lötscher E; Schoeffter P Life Sci; 2003 Jul; 73(9):1151-9. PubMed ID: 12818723 [TBL] [Abstract][Full Text] [Related]
18. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. Citrome L Int J Clin Pract; 2009 Aug; 63(8):1237-48. PubMed ID: 19624791 [TBL] [Abstract][Full Text] [Related]
19. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Nyberg S; Farde L; Eriksson L; Halldin C; Eriksson B Psychopharmacology (Berl); 1993; 110(3):265-72. PubMed ID: 7530376 [TBL] [Abstract][Full Text] [Related]
20. Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Citrome L Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1551-64. PubMed ID: 21034370 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]